Combination Therapy with Ibrexafungerp (Formerly SCY-078), a First-in-Class Triterpenoid Inhibitor of (1→3)-β- d -Glucan Synthesis, and Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis-Reference-Cited by-同舟云学术

Combination Therapy with Ibrexafungerp (Formerly SCY-078), a First-in-Class Triterpenoid Inhibitor of (1→3)-β- d -Glucan Synthesis, and Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis

Published:2020-05-21 Issue:6 Volume:64 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Petraitis Vidmantas¹,Petraitiene Ruta¹,Katragkou Aspasia²,Maung Bo Bo Win¹,Naing Ethan¹,Kavaliauskas Povilas¹,Barat Stephen³,Borroto-Esoda Katyna³,Azie Nkechi³,Angulo David³,Walsh Thomas J.¹⁴⁵

Affiliation:

1. Transplantation-Oncology Infectious Diseases Program, Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine of Cornell University, New York, New York, USA

2. Pediatric Infectious Disease Department, Nationwide Children’s Hospital, The Ohio State University, Columbus, Ohio, USA

3. Scynexis, Inc., Jersey City, New Jersey, USA

4. Department of Pediatrics, Weill Cornell Medicine, New York, New York, USA

5. Department of Microbiology and Immunology, Weill Cornell Medicine, New York, New York, USA

Abstract

Ibrexafungerp (formerly SCY-078) is a semisynthetic triterpenoid and potent (1→3)-β- d -glucan synthase inhibitor. We investigated the in vitro activity, pharmacokinetics, and in vivo efficacy of ibrexafungerp (SCY) alone and in combination with antimold triazole isavuconazole (ISA) against invasive pulmonary aspergillosis (IPA). The combination of ibrexafungerp and isavuconazole in in vitro studies resulted in additive and synergistic interactions against Aspergillus spp.

Funder

Scynexis, Inc.

Save Our Sick Kids Foundation

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.02429-19

Reference31 articles.

1. Prospective Surveillance for Invasive Fungal Infections in Hematopoietic Stem Cell Transplant Recipients, 2001–2006: Overview of the Transplant‐Associated Infection Surveillance Network (TRANSNET) Database

2. The clinical spectrum of pulmonary aspergillosis